Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03301480
Other study ID # PRO17050002
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date July 31, 2017
Est. completion date September 17, 2018

Study information

Verified date February 2019
Source University of Pittsburgh
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study will evaluate the impact of hormonal contraceptives on HIV risk associated with changes to the innate immunity in the female genital tract in a cross-sectional study. HIV risk will be evaluated by the capacity of cervical tissue to replicate HIV when challenged ex vivo and correlated to the number of CD4 T cells, DCs, and macrophages; the capacity of cervicovaginal fluid to inhibit HIV will be correlated to soluble mucosal mediators, and the vaginal microbiota. The lower genital tract samples will be collected from 120 adolescents aged 18-19 (40 using no hormonal contraception, 40 using ENG-I, 40 using LNG-IUS). For comparison, 90 adult women aged 25-45 will be equally distributed between the same groupings.


Recruitment information / eligibility

Status Terminated
Enrollment 120
Est. completion date September 17, 2018
Est. primary completion date September 17, 2018
Accepts healthy volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

1. Meets one of the following age groups (at the time of sample collection):

1. Adolescent aged 18-19

2. Adult aged 25-45

2. Meets one of the following contraception groups:

1. Regular menstrual cycles by participant history (if not using hormonal contraception)

2. Use of ENG-I (i.e. Implanon/Nexplanon) for at least 30 days by participant history

3. Use of LNG-IUS (Mirena or Skyla) for at least 30 days by participant history

3. HIV uninfected Note: HIV testing will be done as part of screening. However, if a woman participated in a recent research study and has an HIV test result available from that study, this will suffice provided the date of the test is within 6 months of the study visit.

4. Willing to undergo pelvic exam and collection of cervical biopsies

5. Willing to provided written informed consent

6. Agree to be sexually abstinent for 48 hours prior to the cervical biopsies and for one week after the biopsies.

Exclusion Criteria:

1. Use of any other hormonal contraception other than ENG-I or LNG-IUS

2. Use of a diaphragm or spermicide for contraception

3. Pregnant or pregnancy within 90 days

4. Currently breastfeeding

5. Currently menstruating/bleeding (at time of specimen collection) Note: participant can return after cessation of bleeding for specimen collection

6. Past participation in more than one study involving cervical biopsies per participant report

7. Cervical biopsies within one month of specimen collection visit

8. Abnormal vaginal discharge or other genital tract symptoms at the time of specimen collection

9. Pelvic findings on the day of specimen collection consistent with cervicitis (i.e. MPC, erythema, edema) or anatomy making cervical biopsies difficult

10. Menopausal

11. Hysterectomy

12. History of malignancy of the genital tract (including cervix, uterus, vagina, and vulva)

13. History of immunosuppression (including HIV infection, diabetes, and chronic steroid use)

14. Known history of a platelet/bleeding/clotting disorder

15. Use of a systemic or vaginal antimicrobial agent within 7 days of specimen collection

16. Use of any vaginal product (i.e. douching, spermicide, lubricant) or device within 7 days of specimen collection Note: tampon use is acceptable

17. Any other condition that in the opinion of the Study Investigator would preclude provision of informed consent or make study participation unsafe, complicate the interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Magee-Womens Hospital of UPMC Pittsburgh Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
University of Pittsburgh National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary HIV replication in cervical tissue as measured by levels of HIV p24/viral transcripts cervical tissue testing baseline
Primary number of immune cells in cervical tissue, including CD45, CD3, CD4, and CD8 and their expression of CCR5, CCR6 and CD69, and CD11c+ DCs and CD14+ macrophages cervical tissue testing baseline
Secondary Prevalence of bacterial vaginosis defined as a Nugent score =7 on a vaginal smear vaginal specimen baseline
Secondary prevalence and quantity of lactobacillus species and bacterial vaginosis associated bacteria as measured by traditional culture methods and quantitative PCR vaginal specimen baseline
Secondary HIV inhibitory activity in mucosal fluid; and soluble mucosal factors identified through pathway analyses and confirmed by targeted ELISA/multiplexing technology (proteases/ anti-proteases, keratin, IFNe, and other molecules) mucosal fluid baseline
See also
  Status Clinical Trial Phase
Recruiting NCT06162897 - Case Management Dyad N/A
Completed NCT03999411 - Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients Phase 4
Completed NCT02528773 - Efficacy of ART to Interrupt HIV Transmission Networks
Active, not recruiting NCT05454839 - Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
Recruiting NCT05322629 - Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women N/A
Completed NCT02579135 - Reducing HIV Risk Among Adolescents: Evaluating Project HEART N/A
Active, not recruiting NCT01790373 - Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence N/A
Not yet recruiting NCT06044792 - The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
Completed NCT04039217 - Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM Phase 4
Active, not recruiting NCT04519970 - Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK) N/A
Completed NCT04124536 - Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women N/A
Recruiting NCT05599581 - Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health N/A
Active, not recruiting NCT04588883 - Strengthening Families Living With HIV in Kenya N/A
Completed NCT02758093 - Speed of Processing Training in Adults With HIV N/A
Completed NCT02500446 - Dolutegravir Impact on Residual Replication Phase 4
Completed NCT03805451 - Life Steps for PrEP for Youth N/A
Active, not recruiting NCT03902431 - Translating the ABCS Into HIV Care N/A
Completed NCT00729391 - Women-Focused HIV Prevention in the Western Cape Phase 2/Phase 3
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Recruiting NCT03589040 - Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant Phase 2